|
Redmile Group invests in both privately held and publicly traded Life Sciences and Medical Device securities. Redmile has disclosed 69 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 3,566,983,000 USD. Redmile Group, LLC's top holdings are Fate Therapeutics, Inc. (US:FATE), Amicus Therapeutics, Inc. (US:FOLD), Deciphera Pharmaceuticals, Inc. (US:DCPH), Biogen Inc. (US:BIIB), and IGM Biosciences, Inc. (US:IGMS). Redmile Group, LLC's new positions include Beam Therapeutics Inc. (US:BEAM), 1Life Healthcare, Inc. (US:ONEM), Zymeworks Inc (US:ZYME), PPD, Inc. (US:PPD), and Twist Bioscience Corp (US:TWST).
|